AG003824

320-67-2 | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one

Chemical structure of 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one, CAS 320-67-2
AG003824
sdsSDS
sdsCOA

Price

$0.00

WARNING This product is not for human or veterinary use.
Request For Quotation
CAS Number 320-67-2
Catalog Number AG003824(AGN-PC-0R7ECF)
Chemical Name 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
EC Number 206-280-2
IUPAC Name 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
InChI InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
InChI Key NMUSYJAQQFHJEW-KVTDHHQDSA-N
MDL Number MFCD00006539
Molecular Formula C8H12N4O5
Molecular Weight 244.2047
NSC Number 758186
SMILES OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc(nc1=O)N
UNII M801H13NRU
Synonyms
5 Azacytidine, 5-Azacytidine, Azacitidine, Azacytidine, NSC 102816, NSC-102816, NSC102816, Vidaza, 5-azacytidine, Azacitidine, 320-67-2, Ladakamycin, Azacytidine, Vidaza, Mylosar, Azacitidina, Azacitidinum, 5-azacitidine, Azacitidinum [INN-Latin], 5-AZAC, Azacitidina [INN-Spanish], 5 AZC, NSC-102816, U-18496, CCRIS 60, UNII-M801H13NRU, NSC102816, 5AzaC, 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one, Antibiotic U 18496, HSDB 6879, WR-183027, 5-AZCR, 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one, EINECS 206-280-2, BRN 0620461, 5-AC, CHEBI:2038, M801H13NRU, 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one, 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one, NSC 102816, MFCD00006539, 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one, 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, NCGC00090851-04, 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one, NCI-C01569, 5-Azacytidine, 99%, 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-, DSSTox_CID_116, U 18496, DSSTox_RID_75378, DSSTox_GSID_20116, wr 183027, mylo sar, Azacitidine [USAN:INN], 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one, SMR000857239, Vidaza (TN), 5-aza-CR, SR-01000075662, Azacitidine (JAN/USAN/INN), Azacitidine [USAN:INN:BAN], NS-17, 1-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-amino-1,3,5-tri azin-2-one, 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one, CAS-320-67-2, Azacitidine(Vidaza), Azacitidine (Vidaza), Antibiotic U18496, U18496, PubChem14167, Spectrum_001262, Spectrum2_000786, Spectrum3_001509, Spectrum4_000922, Spectrum5_001166, MolMap_000062, A 2385, AC1L1T1Y, SCHEMBL3741, CHEMBL1489, Lopac0_000035, BSPBio_003157, KBioGR_001444, KBioGR_002556, KBioSS_001742, KBioSS_002565, KSC222S1T, MLS001333121, MLS001333122, MLS002153249, MLS002548894, DivK1c_000125, SPECTRUM1502111, SPBio_000892, EOS113, GTPL6796, Jsp005945, DTXSID9020116, BCBcMAP01_000083, CTK1C2919, HMS500G07, KBio1_000125, KBio2_001742, KBio2_002556, KBio2_004310, KBio2_005124, KBio2_006878, KBio2_007692, KBio3_002657, KBio3_003034, NMUSYJAQQFHJEW-KVTDHHQDSA-, 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one, pyrimidine antimetabolite: inhibits nucleic acid replication, cMAP_000082, NINDS_000125, NMUSYJAQQFHJEW-KVTDHHQDSA-N, HMS1921J22, HMS2092D08, HMS2231F15, HMS3259D19, HMS3260G11, Pharmakon1600-01502111, ZINC3861768, 5-Azacytidine, >=98% (HPLC), Tox21_111032, Tox21_302985, Tox21_500035, ABP001093, ANW-27256, BDBM50424715, CCG-39046, EBD145507, NSC758186, s1782, SBB066305, AKOS015896938, Tox21_111032_1, AM83944, API0003444, CS-1287, DB00928, LP00035, LS-1189, MCULE-8318770472, NC00672, NSC-758186, NSC103-627, RP28647, RTR-013523, SB18981, 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz, IDI1_000125, 5-azacytidine;Mylosar;Ladakamycin;Vidaza, NCGC00090851-01, NCGC00090851-02, NCGC00090851-03, NCGC00090851-05, NCGC00090851-06, NCGC00090851-07, NCGC00090851-08, NCGC00090851-10, NCGC00178234-01, NCGC00256541-01, NCGC00260720-01, AS-13697, CC-21195, CPD000857239, HY-10586, SAM002264595, SC-09078, SRI-10756_10, SRI-10756_12, ST056940, WR183027, AB2000290, AX8008347, DB-006955, SL-000003, TR-013523, A5777, EU-0100035, FT-0081170, FT-0601307, ST24044344, TL80073599, C11262, D03021, J10124, 33795-EP2275420A1, 33795-EP2295055A2, 33795-EP2295416A2, 33795-EP2298748A2, 33795-EP2298764A1, 33795-EP2298765A1, 33795-EP2305642A2, 33795-EP2311453A1, 33795-EP2311840A1, 124679-EP2270008A1, 124679-EP2292617A1, 124679-EP2295426A1, 124679-EP2295427A1, 320A672, C-14788, J-700085, SR-01000075662-1, SR-01000075662-3, SR-01000075662-7, U-18,496, BRD-K03406345-001-02-1, BRD-K03406345-001-27-8, s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-, Z1522566611, 4-Amino-1-(bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one, s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI), Azacitidine, United States Pharmacopeia (USP) Reference Standard, 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin, Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material, 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-, 5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma, 5AE, InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1, 5 Azacytidine, Ledakamycin, Azacytidine, 5-, FAZARABINE, Vidaz (TN), Azacytidine/5-Azacytidine, D09FAZ, C8H12N4O5, 5-Fluoro-2-nitrobenzoicacid, Pharmion Brand of Azacitidine, 5-fluoro-2-nitro-benzoic Acid, CID9444, 5-Azacytidine, 99% - 1G 1g, Amino-beta-D-ribofuranosyltriazinone, C8-H12-N4-O5, ACN-038132, CS-O-10043, A1907, A10105, D001374, 4-Amino-1-?-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine, S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI), 1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-, 320-98-9, 931-86-2, one,

Related Research Chemicals

CERTIFICATE OF ANALYSIS
Chemical Name: Batch Number:
Chemical Structure: CAS Registry No:
Product ID:
Manufacture Date:
Storage Temperature:
Formula:
Molecular Weight:
Quantity:
Analysis Data:
Test: Result:
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited